|
|
| | αvβ1 integrin-IN-1 Basic information |
| Product Name: | αvβ1 integrin-IN-1 | | Synonyms: | αvβ1 integrin-IN-1;αvβ1 integrinIN1,αvβ1 integrin IN 1;L-Phenylalanine, 1-(phenylsulfonyl)-L-prolyl-4-[[5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-;(S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid;αvβ1 integrin-IN-1, 10 mM in DMSO | | CAS: | 1689540-62-2 | | MF: | C26H34N6O6S | | MW: | 558.65 | | EINECS: | | | Product Categories: | | | Mol File: | 1689540-62-2.mol |  |
| | αvβ1 integrin-IN-1 Chemical Properties |
| density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL | | form | Solid | | pka | 3.59±0.10(Predicted) | | color | White to off-white |
| | αvβ1 integrin-IN-1 Usage And Synthesis |
| Uses | αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects[1]. | | Biological Activity | αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects[1].
αvβ1 integrin-IN-1 (Compound C8) significantly reduces the fibrotic markers in mouse model for liver and lung fibrosis[1]. | | References | [1]. Reed NI, et al. Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors. ACS Med Chem Lett. 2016 Aug 30;7(10):902-907. |
| | αvβ1 integrin-IN-1 Preparation Products And Raw materials |
|